Paeds Vivas · genetics-dysmorphology-and-metabolism
Tuberous sclerosis complex — branching viva
Branching viva on tuberous sclerosis complex: applying the 2012 consensus diagnostic criteria, explaining the hamartin-tuberin-Rheb-mTORC1 mechanism, building surveillance around SEGA and epilepsy, and offering everolimus for growing SEGA and refractory seizures.
On this page
Study tools
Target exams
Opening framework
My framework has four layers. First, the diagnosis — this baby with infantile spasms, hypomelanotic macules and hypsarrhythmia has tuberous sclerosis complex, which I confirm with the 2012 consensus criteria. Second, the mechanism — a loss-of-function variant in TSC1 or TSC2 that abolishes the hamartin-tuberin complex, the GTPase-activating protein that brakes Rheb and mTORC1. Third, the management — vigabatrin first-line for the spasms, then lifelong organ-by-organ surveillance. Fourth, the family — cascade testing and counselling on the 50 per cent autosomal-dominant recurrence risk. [1]
References6ShowHide
- [1]Henske EP, Jóźwiak S, Kingswood JC, et al. Tuberous sclerosis complex. Nat Rev Dis Primers, 2016.PMID 27226234
- [2]Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet, 2008.PMID 18722871
- [3]Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Group. Pediatr Neurol, 2013.PMID 24053982
- [4]Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Group. Pediatr Neurol, 2013.PMID 24053983
- [5]Franz DN, Belousova E, Sparagana S, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol, 2014.PMID 25456370
- [6]French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis complex (EXIST-3). Lancet, 2016.PMID 27613521